Cleveland Clinic Brings The Promise of Telemedicine To Reality
Several people I know who have retired to Florida in recent years still return to the New York area a couple of times a year just to see their doctors. In the majority of cases, these are simply routine follow-ups. But in the era of expanding healthcare technology, smartphones, and tablets, this all seems pretty inefficient, not to mention expensive. Why not just reach out to your practitioner remotely? That’s been the promise of telemedicine for several decades. Now institutions like the Cleveland Clinic are moving it from trial into practice. At the recent Techonomy Health Conference in New York, we had the opportunity to sit down with Dr. Brian Donley, Chief of Staff of the Cleveland Clinic, to speak about their telemedicine program.
Cleveland Clinic-led Study Finds That New Blood Test is More Accurate in Predicting Overall Risk of Prostate Cancer than Standard Prostate-Specific Antigen (PSA)
A team of researchers from Cleveland Clinic, Louis Stokes Cleveland VA Medical Center, Kaiser Permanente Northwest, and other clinical sites have demonstrated that a new blood test known as IsoPSA detects prostate cancer more precisely than current tests in two crucial measures – distinguishing cancer from benign conditions, and identifying patients with high-risk disease.
ERT Acquires Imaging Solution from Cleveland Clinic
ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced the acquisition of ImageIQ, originally established as Cleveland Clinic’s Biomedical Imaging and Analysis Center. The acquisition enables ERT to offer advanced, end-to-end clinical trial imaging analysis using best-in-class technology that delivers compliant data for use in clinical development.
Cleveland HeartLab Adds Two Additional Patents to its Extensive Intellectual Property Position for the Myeloperoxidase (MPO) test, a key predictor of Major Cardiac Events
Cleveland HeartLab Inc. (CHL), the premier cardiovascular disease (CVD) management company, announced today that two new patents for Myeloperoxidase (MPO) testing have been issued: U.S. Patent No. 9,581,597 and U.S. Patent No. 9,612,242. Cleveland HeartLab is the exclusive license holder for MPO testing, which is covered by a number of patents including these two newly issued patents. Originally discovered and developed at the Cleveland Clinic, MPO testing has been recognized in over 100 peer-reviewed publications as a key measure of vascular inflammation, which plays a key role in CVD and cardiovascular events. These new patents will add to Cleveland HeartLab's already existing portfolio of intellectual property rights, which includes 26 issued patents and an additional 15 pending patent applications.
Cleveland Clinic names two new leaders for commercialization divisions
The Cleveland Clinic recently appointed new leaders to its divisions that commercialize medical innovations while creating jobs and attracting talent to Cleveland.
Cleveland Clinic spinoff that makes head impact monitoring technology raises $6 million in new financing
Prevent Biometrics, a Cleveland Clinic spinoff based in suburban Minneapolis that makes head impact monitoring technology, announced it has raised $6 million in new financing.
Cleveland Clinic joint venture spinout to add 200 jobs locally in next three years
A healthcare consultancy and outsourcing organization plans to bring 200 new jobs to Cleveland within the next three years at its new patient coordination center east of downtown.
Cerner adds concussion care platform to athlete management system
Healthcare technology giant Cerner plans to integrate its HealtheAthlete technology with NeuroLogix Technologies’ C3Logix concussion management system.
Bacteria May be Reason Some Foods Cause Heart Disease, Stroke
Researchers trying to figure out how meat causes heart disease came up with another possible explanation Monday: an essential nutrient found in meat and eggs might be a culprit.
They found evidence that choline may feed gut bacteria that in turn produce a compound that makes blood sticky and prone to form clots that can cause heart attacks and strokes.
Innovation center is looking to keep blood flowing
In the decade since its founding, the Global Cardiovascular Innovation Center has reached some milestones its leaders are quick to tick off — and now the center is considering how to sustain its operations as its original funding source wanes.